Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma

Heung Cheol Kim, Ki Tae Suk, Dong Joon Kim, Jai Hoon Yoon, Yeon Soo Kim, Gwang Ho Baik, Jin Bong Kim, Chang Hoon Kim, Hotaik Sung, Jong Young Choi, KwangHyub Han, Seung Ha Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.

Original languageEnglish
Pages (from-to)745-754
Number of pages10
JournalWorld Journal of Gastroenterology
Volume20
Issue number3
DOIs
Publication statusPublished - 2014 Jan 28

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Survival Rate
Ethiodized Oil
Mortality
Tomography
Regression Analysis
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Kim, H. C., Suk, K. T., Kim, D. J., Yoon, J. H., Kim, Y. S., Baik, G. H., ... Park, S. H. (2014). Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World Journal of Gastroenterology, 20(3), 745-754. https://doi.org/10.3748/wjg.v20.i3.745
Kim, Heung Cheol ; Suk, Ki Tae ; Kim, Dong Joon ; Yoon, Jai Hoon ; Kim, Yeon Soo ; Baik, Gwang Ho ; Kim, Jin Bong ; Kim, Chang Hoon ; Sung, Hotaik ; Choi, Jong Young ; Han, KwangHyub ; Park, Seung Ha. / Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. In: World Journal of Gastroenterology. 2014 ; Vol. 20, No. 3. pp. 745-754.
@article{09824f13f1314da4b48363528a5694cb,
title = "Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma",
abstract = "Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91{\%}, 63{\%} and 49{\%}, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96{\%}, 87{\%} and 87{\%} (no risk factors), 89{\%}, 65{\%}, and 35{\%} (1 risk factor), 96{\%}, 48{\%} and unavailable (2 risk factors), and 63{\%}, 17{\%}, and 0{\%} (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.",
author = "Kim, {Heung Cheol} and Suk, {Ki Tae} and Kim, {Dong Joon} and Yoon, {Jai Hoon} and Kim, {Yeon Soo} and Baik, {Gwang Ho} and Kim, {Jin Bong} and Kim, {Chang Hoon} and Hotaik Sung and Choi, {Jong Young} and KwangHyub Han and Park, {Seung Ha}",
year = "2014",
month = "1",
day = "28",
doi = "10.3748/wjg.v20.i3.745",
language = "English",
volume = "20",
pages = "745--754",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "3",

}

Kim, HC, Suk, KT, Kim, DJ, Yoon, JH, Kim, YS, Baik, GH, Kim, JB, Kim, CH, Sung, H, Choi, JY, Han, K & Park, SH 2014, 'Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma', World Journal of Gastroenterology, vol. 20, no. 3, pp. 745-754. https://doi.org/10.3748/wjg.v20.i3.745

Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. / Kim, Heung Cheol; Suk, Ki Tae; Kim, Dong Joon; Yoon, Jai Hoon; Kim, Yeon Soo; Baik, Gwang Ho; Kim, Jin Bong; Kim, Chang Hoon; Sung, Hotaik; Choi, Jong Young; Han, KwangHyub; Park, Seung Ha.

In: World Journal of Gastroenterology, Vol. 20, No. 3, 28.01.2014, p. 745-754.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma

AU - Kim, Heung Cheol

AU - Suk, Ki Tae

AU - Kim, Dong Joon

AU - Yoon, Jai Hoon

AU - Kim, Yeon Soo

AU - Baik, Gwang Ho

AU - Kim, Jin Bong

AU - Kim, Chang Hoon

AU - Sung, Hotaik

AU - Choi, Jong Young

AU - Han, KwangHyub

AU - Park, Seung Ha

PY - 2014/1/28

Y1 - 2014/1/28

N2 - Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.

AB - Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.

UR - http://www.scopus.com/inward/record.url?scp=84892884968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892884968&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i3.745

DO - 10.3748/wjg.v20.i3.745

M3 - Article

VL - 20

SP - 745

EP - 754

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 3

ER -